|
14.04.2015 16:01:00
|
21st Century Oncology, Inc -- Moody's rates 21st Century Oncology's proposed revolver and term loan B1, unsecured notes rated Caa2; B3 CFR affirmed
New York, April 14, 2015 -- Moody's Investors Service assigned B1 ratings to 21st Century Oncology, Inc.'s ("21st Century") proposed $125 million senior secured revolving credit facility and $570 million senior secured term loan. A Caa2 rating was assigned to the company's proposed $400 million unsecured notes. At the same time, Moody's affirmed the company's B3 Corporate Family Rating and B3-PD Probability of Default Rating. The company's Speculative Grade Liquidity Rating ("SGL") was affirmed at SGL-2. The rating outlook remains stable.
Letzte Top-Ranking Nachrichten
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.